Date: 2017-07-26
Type of information: Licensing agreement
Compound:
- PASylation® Technology applied to selected asparaginase product candidates
Company: Jazz Pharmaceuticals (Ireland) XL-Protein (Germany)
Therapeutic area:
Type agreement: licensing
Action mechanism:
- PASylation® technology is a biological alternative to PEGylation that is used to modify and tailor residence time of protein drugs in blood plasma. The PASylation® technology utilizes genetic engineering to fuse a polymer of natural amino acids (Proline, Alanine and/or Serine) with a protein-based therapeutic, thereby enabling manufacture of a fully active protein in various host organisms, including Escherichia coli.
- PAS (Proline, Alanine and/or Serine) sequences are hydrophilic, uncharged biological polymers with PEG-like biophysical properties. In contrast, beside chemical coupling PAS polypeptides offer simple fusion to a biological drug at the genetic level as well as biodegradability, thus preventing tissue accumulation.
Disease:
Details:
- • On July 26, 2017, Jazz Pharmaceuticals announced that it has entered into a license agreement with XL-protein for the rights to develop, manufacture and commercialize products using XLp's PASylation® Technology to extend the plasma half-life of selected asparaginase product candidates. Under the terms of the agreement, Jazz will gain access to XLp's PASylation technology to enable construction of asparaginase molecules intended to extend both the circulating half-life and the duration of therapeutic effect. Through this collaboration with XL-protein, Jazz Pharmaceuticals is working towards its goal of developing an effective, well-tolerated and long-acting recombinant crisantaspase (Erwinase®) that could potentially offer a clinically meaningful therapeutic option for patients with acute lymphoblastic leukemia .
Financial terms:
- Jazz has paid an upfront payment of $2 million and will pay XLp for services and support as specified in the license agreement and for the achievement of certain development, regulatory and commercial milestone events, as well as royalties. Other financial terms are not disclosed.
Latest news:
Is general: Yes
